Second quarter 2010 results are as follows:

• Revenue of $212.0 million, a 31% increase over the $161.6 million reported in the second quarter of 2009.
• GAAP net income for the quarter of $29.8 million, or $0.21 per diluted share, compared to net income of $24.7 million, or $0.18 per diluted share, for the second quarter of 2009. Net income for the second quarter of 2010 included $5.2 million in non-cash interest expense and other items listed in the table entitled “An Itemized Reconciliation Between GAAP and Non-GAAP Net Income.”
• Non-GAAP net income for the quarter of $34.0 million, or $0.26 per diluted share, compared to $29.2 million, or $0.22 per diluted share, for the second quarter of 2009.

Affymetrix, Inc. (NASDAQ:AFFX) today announced that it will develop and commercialize the Axiom(TM) Chinese myDesign(TM) Genotyping Array, the first product that provides maximum power for genome-wide association studies (GWAS) specifically on Chinese populations.

Illumina, Inc. (NASDAQ:ILMN) today announced the launch of its TruSeq SBS Sequencing kit that will enable high-quality paired end reads of 150 base pairs (bp), increase the output of high-quality base calls, and enhance throughput to greater than 95 Gigabases (Gb) of high-quality base pairs per run on Illumina’s Genome Analyzer (GA) sequencing system. The kit, which the company has commenced shipping broadly, is the first in a series of new kits that will further advance data quality, ease of use and economical sequencing on the company’s sequencing platforms. Individual products within the family of TruSeq reagents will be specifically formulated for each Illumina sequencing platform to best leverage the features of that system to provide the highest yield and quality of data.

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, will highlight its innovative offering of products and services for clinical research and specialty diagnostics during the American Association for Clinical Chemistry (AACC) Annual Meeting and Clinical Lab Expo held in Anaheim, California, July 25 - 29, 2010.

Thermo Fisher Scientific Inc., the world leader in serving science, today announced a landmark collaboration that aims to introduce mass spectrometry-based workflows and technologies into Japan to advance personalized medicine and healthcare. The intent of the collaboration between Thermo Fisher’s Biomarker Research Initiatives in Mass Spectrometry (BRIMS) Center and Toshihide Nishimura, professor at the Tokyo Medical University Hospital and Gyorgy Marko-Varga, professor at the Tokyo Medical University Hospital, and Lund University, Sweden is to establish and support a new Biomarker Research Center in Tokyo, Japan. The new Center will focus on biomarker discovery and quantification, disease mechanisms, therapeutic drug monitoring and disease pathophysiology.

Affymetrix, Inc. (NASDAQ:AFFX) today announced that it has released an unparalleled data set based on extensive validation of novel SNPs from the 1000 Genomes Project. This data will give researchers access to more rare mutations for genome-wide association studies and will enable the rapid design of custom arrays for a variety of applications, including the validation of sequencing results.

Illumina, Inc. (NASDAQ:ILMN) today announced the launch of its TruSeq SBS Sequencing kit that will enable high-quality paired end reads of 150 base pairs (bp), increase the output of high-quality base calls, and enhance throughput to greater than 95 Gigabases (Gb) of high-quality base pairs per run on Illumina’s Genome Analyzer (GA) sequencing system. The kit, which the company has commenced shipping broadly, is the first in a series of new kits that will further advance data quality, ease of use and economical sequencing on the company’s sequencing platforms. Individual products within the family of TruSeq reagents will be specifically formulated for each Illumina sequencing platform to best leverage the features of that system to provide the highest yield and quality of data.

Roche (SIX: RO, ROG; OTCQX: RHHBY) and Exiqon (NASDAQ OMX: EXQ) join marketing forces for Roche Applied Science´s RealTime ready assays and Exiqon`s miRCURY LNA™ Universal RT microRNA qPCR system. As indicated by respective links on their websites, each system will complement the cooperator ´s product portfolio. A bundle of measures like webinars and seminars and linked internet appearances are planned to promote the joint offer. Financial terms of the agreement were not disclosed.

Dolomite, a world leader in microfluidic design and manufacture, has introduced the modular Syringe-based Droplet Starter System, which enables users to produce more than 10,000 monodispersed droplets per second, ranging from Ø 20 to 250µm. Operating over a wide flow range, from 0.1µl/min to 10ml/min, this chemically resistant system is ideal for initial concept work and experimentation towards the development of high throughput droplet systems. Including a range of Droplet Junction Chips with different geometries, channel sizes and surface properties, the Syringe-based Droplet Starter System enables the formation of both water-in-oil and oil-in-water droplets.

Thermo Fisher Scientific Inc., the world leader in serving science, today announced a new application note entitled “Enhancing Phosphotyrosine Proteome Coverage using a Combined ETD and CID Approach on a LTQ Orbitrap XL ETD”. The application note is a result of the cooperation with the Netherlands Proteomic Centre and in particular the
Biomolecular Mass Spectrometry and Proteomics Group at Utrecht University,headed by Albert Heck. It demonstrates how electron transfer dissociation (ETD) and collision induced dissociation (CID) are complementary fragmentation techniques, that when used together on the Thermo Scientific LTQ Orbitrap XL ETD mass spectrometer, provide significantly greater phosphoproteome coverage than mass spectrometry (MS) methods relying on CID alone. By using intelligent data-dependent decision tree (DDDT) logic to choose whether to perform ETD or CID in real-time, significantly more phosphopeptides can be identified, along with unambiguous determination of the phosphorylation sites.

Affymetrix, Inc., (NASDAQ:AFFX) today reported its operating results for the second quarter of 2010. Total revenue for the quarter was $71.7 million, in line with previously announced expectations, as compared to total revenue of $81.6 million in the second quarter of 2009.

Affymetrix, Inc. (NASDAQ:AFFX) today announced the launch of QuantiGene(R) ViewRNA Assayformats, which enable a new era of “in situ multiplex gene expression analysis” by allowing drug screening of native cells and advancing the pace of biomarker disease research and stem cell studies. These in situ assays enable researchers to visualize gene expression in individual cells at an unprecedented level of sensitivity and speed.

Affymetrix, Inc. (NASDAQ:AFFX) today announced that it has launched Axiom(TM) Custom Genotyping Arrays, the newest addition to the Axiom Genotyping Solution. Researchers can now leverage Affymetrix’ Axiom Genomic Database, the world’s largest collection of validated common and rare SNPs, to create custom arrays containing 50,000 to as many as 2.6 million SNPs. This inherent flexibility allows researchers to conduct genome-wide association, replication, fine mapping, and candidate gene studies on a single platform.

GE Healthcare, a unit of General Electric Company (NYSE: GE), will host ‘DiPIA 2010’, a leading forum for discussion of the latest developments and trends in the field of biomolecular interaction and stability analysis, across the entire spectrum of biological research. The symposium will be held in Barcelona, Spain from 17-20 October at the Pullman Barcelona Skipper Hotel.

Affymetrix, Inc. (NASDAQ:AFFX) today announced that it has launched Axiom(TM) Custom Genotyping Arrays, the newest addition to the Axiom Genotyping Solution. Researchers can now leverage Affymetrix’ Axiom Genomic Database, the world’s largest collection of validated common and rare SNPs, to create custom arrays containing 50,000 to as many as 2.6 million SNPs. This inherent flexibility allows researchers to conduct genome-wide association, replication, fine mapping, and candidate gene studies on a single platform.